Could a gut antibiotic shrink fatty liver? new trial begins
NCT ID NCT07381257
First seen Feb 02, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests whether rifaximin-α, an antibiotic that works in the gut, can reduce liver fat in people with metabolic fatty liver disease (MASLD). About 60 adults will take the drug or follow standard diet and exercise advice for 24 weeks. The goal is to see if the drug safely lowers liver fat and improves health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng Hospital, Naval Medical University, shanghai, China
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.